Principal Financial Group Inc. Has $1.50 Million Stock Holdings in Delcath Systems, Inc. (NASDAQ:DCTH)

Principal Financial Group Inc. raised its holdings in Delcath Systems, Inc. (NASDAQ:DCTH) by 2.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 117,620 shares of the company’s stock after acquiring an additional 2,437 shares during the quarter. Principal Financial Group Inc. owned about 0.35% of Delcath Systems worth $1,497,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Soleus Capital Management L.P. bought a new position in Delcath Systems during the fourth quarter worth $9,644,000. Vivo Capital LLC increased its position in Delcath Systems by 71.4% during the fourth quarter. Vivo Capital LLC now owns 1,708,579 shares of the company’s stock worth $20,571,000 after acquiring an additional 711,574 shares during the period. Gilder Gagnon Howe & Co. LLC bought a new position in Delcath Systems during the fourth quarter worth $7,371,000. Jane Street Group LLC increased its position in Delcath Systems by 1,364.6% during the fourth quarter. Jane Street Group LLC now owns 178,797 shares of the company’s stock worth $2,153,000 after acquiring an additional 166,589 shares during the period. Finally, Silverarc Capital Management LLC bought a new position in Delcath Systems during the fourth quarter worth $1,870,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Trading Down 0.6%

NASDAQ DCTH opened at $11.25 on Friday. The stock has a 50 day moving average of $14.59 and a 200-day moving average of $13.82. Delcath Systems, Inc. has a 12 month low of $7.17 and a 12 month high of $18.23. The company has a market cap of $391.79 million, a PE ratio of -22.50 and a beta of 0.87.

Delcath Systems (NASDAQ:DCTH) last posted its earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 29.44% and a negative net margin of 26.38%. The firm had revenue of $19.80 million for the quarter, compared to analyst estimates of $16.83 million. As a group, sell-side analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DCTH. Stephens reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Delcath Systems in a report on Monday, June 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price (up previously from $24.00) on shares of Delcath Systems in a report on Friday, May 23rd. Finally, Wall Street Zen downgraded shares of Delcath Systems from a “buy” rating to a “hold” rating in a research report on Saturday, July 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.